All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
Managing anemia in patients with MF
Do you know... In myelofibrosis (MF)-related anemia, which statement best describes the role of luspatercept?
Anemia is present in approximately 45% of patients with myelofibrosis (MF) at diagnosis and becomes increasingly common as the disease progresses.1 It is associated with reduced quality of life, red blood cell (RBC) transfusion dependence, and inferior survival.1 Despite advances in MF management, anemia remains a major unmet clinical need, driving the development of targeted therapies such as luspatercept.1–3
We summarize the burden of MF-related anemia, the mechanism of action of luspatercept, and key findings from the INDEPENDENCE, and ODYSSEY clinical trials, highlighting the evolving role of targeted approaches in the management of MF-related anemia.4,5
This educational resource is independently supported by BMS. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Do you include basal serum tryptase (bST) testing in the diagnostic evaluation of patients with MPN?
.jpeg)